Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling.

Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford St., Cambridge, Massachusetts 02138, USA.
Molecular &amp Cellular Proteomics (Impact Factor: 7.25). 02/2011; 10(4):M110.005363. DOI: 10.1074/mcp.M110.005363
Source: PubMed

ABSTRACT Lysate microarrays (reverse-phase protein arrays) hold great promise as a tool for systems-level investigations of signaling and multiplexed analyses of disease biomarkers. To date, however, widespread use of this technology has been limited by questions concerning data quality and the specificity of detection reagents. To address these concerns, we developed a strategy to identify high-quality reagents for use with lysate microarrays. In total, we tested 383 antibodies for their ability to quantify changes in protein abundance or modification in 20 biological contexts across 17 cell lines. Antibodies yielding significant differences in signal were further evaluated by immunoblotting and 82 passed our rigorous criteria. The large-scale data set from our screen revealed that cell fate decisions are encoded not just by the identities of proteins that are activated, but by differences in their signaling dynamics as well. Overall, our list of validated antibodies and associated protocols establish lysate microarrays as a robust tool for systems biology.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Reverse Phase Protein Array (RPPA) technology introduced a miniaturized antigen-down or dot-blot immunoassay suitable for quantifying the relative or absolute abundance of total protein levels and post-translational modifications across a variety of biological samples including cultured cells, tissues, and body fluids. Recent evolution of RPPA combined with more sophisticated sample handling, optical detection, quality control, and better quality affinity-reagents provides exquisite sensitivity and high sample throughput at a reasonable cost per sample. This facilitates large-scale multiplex analysis of multiple post-translational markers across samples from in vitro, preclinical, or clinical samples. The technical power of RPPA is stimulating the application and widespread adoption of RPPA methods within academic, clinical and industrial research laboratories. Advances in RPPA technology now offer scientists the opportunity to quantify protein analytes with high precision, sensitivity, throughput and robustness. As such, adopters of RPPA technology have recognized critical success factors for useful and maximum exploitation of RPPA technologies: 1. Preservation and optimization of pre-analytical sample quality. 2. Application of validated high-affinity and specific antibody (or other protein affinity) detection reagents. 3. Dedicated informatics solutions to ensure accurate and robust quantification of protein analytes. 4. Quality assured procedures and data analysis workflows compatible with application within regulated clinical environments. In 2011 and 2012, the first two Global RPPA workshops were held in the USA and Europe, respectively. These workshops provided an opportunity for RPPA laboratories, vendors and users to share and discuss results, latest technology platforms, best practices and future challenges and opportunities. The outcomes of the 2011 and 2012 workshops included a number of key opportunities to advance the RPPA field and provide added benefit to existing and future participants of the RPPA research community. The purpose of this report is to share and disseminate, as a community, current knowledge and future directions of the RPPA technology.
    Molecular &amp Cellular Proteomics 04/2014; 13(7). DOI:10.1074/mcp.O113.034918 · 7.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Soluble growth factors present in the microenvironment play a major role in tumor development, invasion, metastasis, and responsiveness to targeted therapies. While the biochemistry of growth factor-dependent signal transduction has been studied extensively in individual cell types, relatively little systematic data is available across genetically diverse cell lines. We describe a quantitative and comparative dataset focused on immediate-early signaling that regulates the AKT (AKT1/2/3) and ERK (MAPK1/3) pathways in a canonical panel of well-characterized breast cancer lines; we also provide interactive web-based tools to facilitate follow-on analysis of the data. Our findings show that breast cancers are diverse with respect to ligand sensitivity and signaling biochemistry. Surprisingly, triple negative breast cancers (TNBCs; which express low levels of ErbB2, progesterone, and estrogen receptors) are the most broadly responsive to growth factors and HER2amp cancers (which overexpress ErbB2) the least. The ratio of ERK to AKT activation varies with ligand and subtype, with a systematic bias in favor of ERK in hormone receptor positive (HR+) cells. The factors that correlate with growth-factor responsiveness depend on whether fold-change or absolute activity is considered the key biological variable, and it differs between ERK and AKT pathways. Responses to growth factors are highly diverse across breast cancer cell lines, even within the same subtype. A simple four-part heuristic suggests that diversity arises from variation in receptor abundance, an ERK/AKT bias that depends on ligand identity, a set of factors common to all receptors that varies in abundance or activity with cell line, and "indirect negative regulation" by ErbB2. This analysis sets the stage for development of a mechanistic and predictive model of growth factors signaling in diverse cancer lines. Interactive tools for looking up these results and downloading raw data are available at
    BMC Biology 03/2014; 12(1):20. DOI:10.1186/1741-7007-12-20 · 7.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the emergence of dozens of oncogenic targets and corresponding molecularly targeted therapies, in most cases tumours continue to progress or recur due to therapeutic resistance. In the present review, we highlight the ability of MS-based phosphoproteomics to quantify oncogenic signalling networks driving tumour growth and invasion, as well as those networks enabling tumour cell survival in the presence of chemotherapeutics. Quantitative protein phosphorylation profiling will facilitate the design and development of optimal therapeutic strategies targeting the initial tumour while simultaneously blocking the predominant resistance mechanisms.
    Biochemical Society Transactions 08/2014; 42(4):758-64. DOI:10.1042/BST20140038 · 3.24 Impact Factor